FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to immunology, and can be used for treating a malignant tumour. For this purpose, the immunotherapeutic composition contains: a) a yeast carrier and b) a malignant tumour antigen comprising a Brachyury antigen, where the Brachyury antigen comprises SEQ ID NO: 6, positions 2–435 in SEQ ID NO: 6, SEQ ID NO: 18, positions 2–435 in SEQ ID NO: 18 or an amino acid sequence which is at least 85 % identical to SEQ ID NO: 18 and comprises replacing leucine in position 254 on valine. Group of inventions also relates to a method of treating a malignant tumour in an individual.
EFFECT: use of the given group of inventions enables to elicit a response of Brachyury T-specific cells and/or to increase a pre-existing initial response of Brachyury T-specific cells.
27 cl, 8 dwg, 10 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOTHERAPEUTIC COMPOSITIONS BASED ON YEAST WITH BRACHYURY | 2012 |
|
RU2619850C2 |
| IMMUNOTHERAPEUTIC COMPOSITIONS ON THE BASIS OF YEAST-MUC1 AND METHODS OF THEIR USE | 2012 |
|
RU2642300C2 |
| YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA | 2014 |
|
RU2679806C2 |
| RECOMBINANT IMMUNOTOXIN AIMED AT MESOTHELIN | 2012 |
|
RU2600067C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| INTRACELLULAR DOMAIN OF PROTEIN HER-2/NEU FOR PROPHYLAXIS AND TREATMENT OF MALIGNANCY | 1996 |
|
RU2236461C2 |
| TRANSPOSASE POLYPEPTIDES AND USE THEREOF | 2016 |
|
RU2735700C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| MYCOBACTERIAL ANTIGEN COMPOSITION | 2011 |
|
RU2576007C2 |
